The U.S. Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceuticals’ NRXP lead drug ZYESAMI (aviptadil) for subgroup of patients with critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir.
The Emergency Use Authorization (EUA) application was supported by data readout from a post-hoc subgroup analysis.
Robert Besthof, interim CEO, commented : "Though disappointing, this decision by the FDA is not unexpected, given that they had already recently declined Breakthrough Therapy Designation for ZYESAMI. We will evaluate the options for ZYESAMI in COVID-19 respiratory failure and other lung disorders once we receive the full data set from the National Institutes of Health (NIH).”
The company said that team NRx has been highly focused on the development of NRX-101 for bipolar depression in patients with Acute and Sub-Acute Suicidality.
NRx Pharmaceuticals shares are trading high 1 percent at $0.61 on Friday during pre-market session.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.